Aeglea BioTherapeutics logo
Aeglea BioTherapeutics AGLE

Quarterly report 2025-Q3
added 11-04-2025

report update icon

Aeglea BioTherapeutics Financial Statements 2011-2025 | AGLE

Annual Financial Statements Aeglea BioTherapeutics

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

724 M 433 M 1.35 M 12.5 M 420 M 226 M 187 M 104 M 39.3 M - - - - -

Shares

60.3 M 36.1 M 3.37 M 2.63 M 53.4 M 31.9 M 20.8 M 15.1 M 9.79 M - - - - -

Historical Prices

12 12 0.4 4.75 7.87 7.64 7.49 5.41 4.35 - - - - -

Net Income

-208 M -339 M -83.8 M -65.8 M -80.9 M -78.3 M -44.3 M -27.2 M -21.7 M -11.3 M -10.3 M - - -

Revenue

- 886 K 2.33 M 18.7 M 21.8 K - 3.89 M 5.2 M 4.63 M 6.08 M - - - -

Operating Income

-209 M -242 M -84.8 M -65.6 M -81.5 M -80.3 M -45.5 M -27.7 M -21.9 M -11.3 M -8.9 M - - -

Interest Expense

-20.7 M -19.1 M -7 K -122 K -5 K -63 K -57 K -42 K -36 K -2 K - - - -

EBITDA

- -242 M -83.2 M -64.1 M -80.5 M -79.9 M -45.2 M -27.4 M -21.8 M -11.2 M -7.44 M - - -

Operating Expenses

209 M 243 M 87.1 M 84.4 M 81.5 M 80.3 M 49.4 M 32.9 M 26.5 M 17.4 M - - - -

General and Administrative Expenses

45.8 M 39.9 M 28.5 M 27.3 M 21.8 M 15.7 M 12.6 M 10.1 M 8.39 M 5.95 M 2.07 M - - -

All numbers in USD currency

Quarterly Income Statement Aeglea BioTherapeutics

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

60.5 M 60.4 M 60.3 M 60.3 M 50.9 M 45.3 M 36.5 M 36.1 M 4.29 M 3.82 M 3.77 M 2.61 M 3.77 M 82.2 M 66 M 49.4 M 65.8 M 65.6 M 65.6 M 48 M 62.2 M 52.9 M 33.1 M 29.1 M 32.9 M 32.8 M 29 M 24.1 M 22 M 20.6 M 16.7 M 16.7 M 16.4 M 14.1 M 13.4 M 13.4 M 13.3 M 11.8 M 641 K 757 K 613 K 586 K 573 K - - - - - - - - - - - - - - - -

Net Income

-11.2 M -36.7 M -44.8 M - -69 M -38.8 M -43.9 M - -40.1 M -217 M -18.4 M - -18.2 M -22.3 M -24.4 M - -20.3 M -6.83 M -18.2 M -22.7 M -18 M -21.4 M -18.7 M -21.5 M -21.6 M -18 M -17.2 M -14.9 M -11.9 M -9.41 M -8.12 M -6.48 M -7.87 M -6.63 M -6.25 M -5.48 M -6.24 M -5.43 M -4.55 M -3.99 M -3.41 M -1.43 M -2.47 M - - - - - - - - - - - - - - - -

Revenue

- - - - - - - - - 688 K 198 K - 174 K 625 K 1.36 M - 1.4 M 13.7 M - - - - - - - - - - - 2.38 M 1.51 M 1.48 M 1.26 M 1.48 M 982 K - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-56.9 M -41.9 M -53.6 M - -55.4 M -44.1 M -47.8 M - -18.3 M -159 M -18.8 M - -18.8 M -22.4 M -24.4 M - -20.3 M -6.7 M -18.2 M -22.8 M -18.1 M -21.6 M -19 M -21.9 M -22.1 M -18.6 M -17.7 M -15.3 M -12.2 M -9.67 M -8.24 M -6.63 M -8 M -6.72 M -6.33 M -5.54 M -6.3 M -5.5 M -4.57 M -4 M -3.42 M -1.43 M -2.47 M - - - - - - - - - - - - - - - -

Interest Expense

40.3 M -656 K 2.29 M - -18.8 M -610 K -483 K - 2.34 M -8 K -72 K - 24 K 5 K -30 K - -24 K -52 K -31 K - 2 K -19 K -6 K - -12 K -16 K -17 K - -13 K -7 K -17 K - -12 K -12 K -11 K - -9 K -9 K -6 K - -1 K - - - - - - - - - - - - - - - - - -

EBITDA

- - - - - - - - - - -18.4 M - -17.6 M -22.4 M -24 M - -19.1 M -6.7 M -17.9 M -22.8 M -17.5 M -21.2 M -18.9 M -21.9 M -21.8 M -18.4 M -17.6 M -15.3 M -12 M -9.52 M -8.18 M -6.63 M -7.82 M -6.61 M -6.28 M -5.54 M -6.2 M -5.43 M -4.54 M -4 M -3.36 M -1.4 M -2.45 M - - - - - - - - - - - - - - - -

Operating Expenses

56.9 M 41.9 M 53.6 M - 55.4 M 44.1 M 47.8 M - 18.3 M 160 M 19 M - 18.9 M 23 M 25.8 M - 21.7 M 20.4 M 18.2 M - 18.1 M 21.6 M 19 M - 22.1 M 18.6 M 17.7 M - 12.2 M 12 M 9.76 M - 9.26 M 8.2 M 7.31 M - 7.45 M 6.87 M 5.43 M - 4.49 M 4.86 M 2.47 M - - - - - - - - - - - - - - - -

General and Administrative Expenses

11.6 M 11.8 M 11.9 M - 10.6 M 11.5 M 12.8 M - 8.58 M 12.1 M 5.23 M - 6.95 M 7.68 M 8.82 M - 6.84 M 6.82 M 6.35 M - 5.67 M 4.69 M 4.46 M - 4.31 M 3.82 M 3.27 M - 3.31 M 2.93 M 2.88 M - 3.02 M 2.36 M 2.36 M - 2.06 M 2.45 M 1.83 M - 1.36 M 2.12 M 847 K - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Aeglea BioTherapeutics AGLE
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Aeglea BioTherapeutics plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
AbbVie AbbVie
ABBV
$ 223.01 -0.99 % $ 395 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.68 1.85 % $ 777 M canadaCanada
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.38 3.21 % $ 261 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 212.3 5.5 % $ 5 B danmarkDanmark
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
BioVie BioVie
BIVI
$ 1.54 -2.53 % $ 2.28 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 1.33 -1.48 % $ 7.25 M chinaChina
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.4 1.49 % $ 8.18 B australiaAustralia
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
$ 90.34 -1.28 % $ 96.9 B britainBritain
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 25.76 0.19 % $ 1.25 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 9.53 -1.19 % $ 140 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.33 2.3 % $ 14.6 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Axon Enterprise Axon Enterprise
AXON
$ 586.28 3.15 % $ 44.4 B usaUSA
Biogen Biogen
BIIB
$ 173.03 -2.55 % $ 25.2 B usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 0.29 -5.01 % $ 631 M israelIsrael
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
$ 12.91 0.78 % $ 531 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 95.9 0.17 % $ 27.2 B germanyGermany
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 11.55 8.86 % $ 747 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
- - $ 40.5 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 15.32 5.73 % $ 1.01 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Cerus Corporation Cerus Corporation
CERS
$ 2.14 13.23 % $ 395 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 9.15 -0.44 % $ 1.47 B britainBritain
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 3.81 -5.35 % $ 46.6 M usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 51.05 -0.32 % $ 103 B usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 5.5 0.46 % $ 118 M usaUSA
ADiTx Therapeutics ADiTx Therapeutics
ADTX
$ 2.36 -7.29 % $ 31.1 K usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 2.1 -4.34 % $ 5.32 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.42 6.77 % $ 134 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 3.22 -2.72 % $ 908 M israelIsrael
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 28.33 0.5 % $ 1.82 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia